Adenovirus-based overexpression of tissue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumor necrosis factor α transgenic mice

Arthritis and Rheumatism

Volumn 44, Issue 12, 2001, Pages 2888-2898

  Schett, Georg ^a,b   Hayer, Silvia ^a   Tohidast Akrad, Makiyeh ^c   Schmid, Beatrice Jahn ^a   Lang, Susanne ^a   Türk, Birgit ^a   Kainberger, Franz ^a   Haralambous, Sylva ^d   Kollias, George ^d   Newby, Andrew C ^e   Xu, Qingbo ^f,g   Steiner, Günter ^a   Smolen, Josef ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^d HELLENIC PASTEUR INSTITUTE   (Greece)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

^f ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^g ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; GENE THERAPY; HISTOLOGY; IN VIVO STUDY; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; TISSUE INJURY; TRANSGENIC MOUSE;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD; ARTHRITIS; ARTHROGRAPHY; AUTOANTIBODIES; GENE EXPRESSION REGULATION, VIRAL; GENE TRANSFER TECHNIQUES; HUMANS; INTERLEUKIN-6; JOINTS; LAC OPERON; MATRIX METALLOPROTEINASE 3; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, TRANSGENIC; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035676661     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200112)44:12<2888::AID-ART477>3.0.CO;2-3     Document Type: Article

References (57)

1. Role of cytokines in rheumatoid arthritis
2. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis
3. Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice
4. DBA/1 mice expressing the human TNF-α transgene develop a severe, erosive arthritis: Characterization of the cytokine cascade and cellular composition
5. Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis
6. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo
7. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
8. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis
9. Infliximab and methotrexate in the treatment of rheumatoid arthritis
10. Matrix metalloproteinases, IL-6, and nitric oxide in rat antigen-induced arthritis
11. Cloning of the gene for interstitial collagenase-3 (matrix metalloproteinase-13) from rabbit synovial fibroblasts: Differential expression with collagenase-1 (matrix metalloproteinase-1)
12. Matrix metalloproteinase-8 is expressed in rheumatoid synovial fibroblasts and endothelial cells: Regulation by tumor necross factor alpha and doxycycline
13. TNF-alpha-mediated expression of membrane-type matrix metalloproteinase in rheumatoid synovial fibroblasts
14. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: Radiologic progression and correlation of Genant and Larsen scores
15. Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent
16. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis
17. Bone resorption by osteoclasts
18. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor
19. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice
20. Differential expression of cathepsins B and L compared with matrix metalloproteinases and their respective inhibitors in rheumatoid arthritis and osteoarthritis: A parallel investigation by semiquantitative reverse transcriptase-polymerase chain reaction and immunohistochemistry
21. Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis
22. Collagenase-3 (MMP-13) is expressed during human fetal ossification and re-expressed in postnatal bone remodeling and in rheumatoid arthritis
23. Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium
24. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: Different profiles in trauma and rheumatoid arthritis
25. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease: Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers
26. Levels of rheumatoid factor isotypes, metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in synovial fluid from various arthritides
27. Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis
28. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues: Clinical and experimental applications
29. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy
30. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in rheumatoid synovium
31. 342 site coincides with the initiation of collagen damage in murine antigen-induced arthritis: A pivotal role for stromelysin 1 in matrix metalloproteinase activity
32. Collagenase, cathepsin B and cathepsin L gene expression in the synovial membrane of patients with early inflammatory arthritis
33. Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis
34. Serum matrix metalloproteinase-3 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis
35. Imbalance between interstitial collagenase and tissue inhibitor of metalloproteinases 1 in synoviocytes and fibroblasts upon direct contact with stimulated T lymphocytes: Involvement of membrane-associated cytokines
36. Bone resorption induced by parathyroid hormone is strikingly diminished in collagenase-resistant mutant mice
37. Insights into MMP-TIMP interactions
38. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1
39. Matrix metalloproteinases, but not cathepsins B, H, and L or their inhibitors in peripheral blood of patients with rheumatoid arthritis are potentially useful markers of disease activity
40. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis and osteoarthritis
41. Rheumatoid synovial endothelial cells secrete decreased levels of tissue inhibitor of MMP (TIMP1)
42. Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor
43. Suppression of adjuvant arthritis of rats by a novel matrix metalloproteinase-inhibitor
44. Thirty-six years in the clinic without an MMP inhibitor: What hath collagenase wrought?
45. Using inhibitors of metalloproteinases to treat arthritis: Easier said than done?
46. Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins
47. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3
48. Purification and partial sequencing of the nuclear autoantigen RA33 shows that it is indistinguishable from the A2 protein of the heterogeneous nuclear ribonucleoprotein complex
49. Hand radiography of 200 patients with rheumatoid arthritis repeated after an interval of one year
50. Autoantibody formation in TNF-α transgenic mice: A link between cytokine overexpression and autoimmunity in rheumatoid arthritis
51. B and T cell responses to the spliceosomal heterogeneous nuclear ribonucleoproteins A2 and B1 in normal and lupus mice
52. Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures
53. Matrix metalloproteinases and processing of pro-TNF-alpha
54. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity
55. Cell growthpromoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2)
56. Pannus and pannocytes: Alternative models of joint destruction in rheumatoid arthritis
57. Aggrecan degradation in human cartilage: Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints